NEUROCRINE BIOSCIENCES, INC

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$23.7M

Filings

145

Firms Hired

Active Period

2017–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$2,820,000	13	4
2025	$3,600,000	22	5
2024	$3,320,000	21	5
2023	$3,120,000	20	5
2022	$4,080,000	22	5
2021	$3,470,000	20	5
2020	$2,620,000	11	3
2019	$680,000	7	2
2018	—	4	1
2017	—	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
NEUROCRINE BIOSCIENCES, INC	$23,710,000	33
BGR GOVERNMENT AFFAIRS	—	42
TARPLIN, DOWNS & YOUNG, LLC	—	25
CAPITOL COUNSEL LLC	—	21
RICCHETTI INCORPORATED	—	19
LMH STRATEGIC SOLUTIONS	—	5

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	138
SENATE	138
Health & Human Services, Dept of (HHS)	45
Centers For Medicare and Medicaid Services (CMS)	44
Executive Office of the President (EOP)	4
White House Office	3

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	95
Medicare/Medicaid	Medicare/Medicaid	89
Budget/Appropriations	Budget/Appropriations	65
Pharmacy	Pharmacy	64
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	24
Insurance	Insurance	3
Financial Institutions/Investments/Securities	Financial Institutions/Investments/Securities	2
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3432118th Congress

Telemental Health Care Access Act of 2023

2026 · third_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 3432

H.R. 7024118th Congress

Tax Relief for American Families and Workers Act of 2024

2026 · third_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 7024

H.R. 7623118th Congress

Telehealth Modernization Act of 2024

2026 · third_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 7623

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · third_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 1492

Show 21 more cited filings

H.R. 946119th Congress

ORPHAN Cures Act

2026 · third_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 946

S. 832119th Congress

EPIC Act of 2025

2026 · third_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: S. 832

H.R. 3432118th Congress

Telemental Health Care Access Act of 2023

2026 · second_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 3432

H.R. 7024118th Congress

Tax Relief for American Families and Workers Act of 2024

2026 · second_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 7024

H.R. 7623118th Congress

Telehealth Modernization Act of 2024

2026 · second_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 7623

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · second_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 1492

H.R. 946119th Congress

ORPHAN Cures Act

2026 · second_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 946

S. 832119th Congress

EPIC Act of 2025

2026 · second_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: S. 832

H.R. 3432118th Congress

Telemental Health Care Access Act of 2023

2026 · first_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 3432

H.R. 7024118th Congress

Tax Relief for American Families and Workers Act of 2024

2026 · first_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 7024

H.R. 7623118th Congress

Telehealth Modernization Act of 2024

2026 · first_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 7623

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · first_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 1492

H.R. 946119th Congress

ORPHAN Cures Act

2026 · first_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: H.R. 946

S. 832119th Congress

EPIC Act of 2025

2026 · first_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $940,000 · Firm income: —

Matched citations: S. 832

H.R. 3432118th Congress

Telemental Health Care Access Act of 2023

2025 · fourth_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $900,000 · Firm income: —

Matched citations: H.R. 3432

H.R. 7024118th Congress

Tax Relief for American Families and Workers Act of 2024

2025 · fourth_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.

Client expense: $900,000 · Firm income: —

Matched citations: H.R. 7024

H.R. 7623118th Congress

Telehealth Modernization Act of 2024

2025 · fourth_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $900,000 · Firm income: —

Matched citations: H.R. 7623

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · fourth_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $900,000 · Firm income: —

Matched citations: H.R. 1492

H.R. 946119th Congress

ORPHAN Cures Act

2025 · fourth_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $900,000 · Firm income: —

Matched citations: H.R. 946

S. 832119th Congress

EPIC Act of 2025

2025 · fourth_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing

Client expense: $900,000 · Firm income: —

Matched citations: S. 832

H.R. 3432118th Congress

Telemental Health Care Access Act of 2023

2025 · third_quarter · Firm: NEUROCRINE BIOSCIENCES, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.

Client expense: $900,000 · Firm income: —

Matched citations: H.R. 3432

Source: Senate LDA

NEUROCRINE BIOSCIENCES, INC — Lobbying Disclosure | Poliscope